[go: up one dir, main page]

AR040280A2 - Procedimiento para aumentar su solubilidad en un medio acuoso - Google Patents

Procedimiento para aumentar su solubilidad en un medio acuoso

Info

Publication number
AR040280A2
AR040280A2 ARP030102180A ARP030102180A AR040280A2 AR 040280 A2 AR040280 A2 AR 040280A2 AR P030102180 A ARP030102180 A AR P030102180A AR P030102180 A ARP030102180 A AR P030102180A AR 040280 A2 AR040280 A2 AR 040280A2
Authority
AR
Argentina
Prior art keywords
solubility
procedure
increase
water media
sertraline
Prior art date
Application number
ARP030102180A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR040280(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR040280A2 publication Critical patent/AR040280A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedimiento para aumentar la solubilidad de la sertralina en un medio de uso acuoso que contiene ion cloruro, que comprende anadir la mencionada sertralina al mencionado medio de uso en una composición de materia que adicionalmente comprende un agente solubilizante.
ARP030102180A 1997-07-01 2003-06-19 Procedimiento para aumentar su solubilidad en un medio acuoso AR040280A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01

Publications (1)

Publication Number Publication Date
AR040280A2 true AR040280A2 (es) 2005-03-23

Family

ID=21971159

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP980103146A AR015917A1 (es) 1997-07-01 1998-06-29 Composiciones de materia que contiene sertralina y procedimiento para aumentar su solubilidad en un medio acuoso
ARP030102179A AR040279A2 (es) 1997-07-01 2003-06-19 Composiciones que contiene sal de sertralina
ARP030102180A AR040280A2 (es) 1997-07-01 2003-06-19 Procedimiento para aumentar su solubilidad en un medio acuoso

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP980103146A AR015917A1 (es) 1997-07-01 1998-06-29 Composiciones de materia que contiene sertralina y procedimiento para aumentar su solubilidad en un medio acuoso
ARP030102179A AR040279A2 (es) 1997-07-01 2003-06-19 Composiciones que contiene sal de sertralina

Country Status (34)

Country Link
EP (1) EP0999829A1 (es)
JP (1) JP2000514100A (es)
KR (1) KR100366373B1 (es)
CN (1) CN1261794A (es)
AP (1) AP1192A (es)
AR (3) AR015917A1 (es)
AU (1) AU742535B2 (es)
BG (1) BG103918A (es)
BR (1) BR9810739A (es)
CA (1) CA2290974C (es)
CO (1) CO4940495A1 (es)
DZ (1) DZ2548A1 (es)
EA (1) EA002481B1 (es)
HN (1) HN1998000102A (es)
HR (1) HRP980377A2 (es)
HU (1) HUP0002236A3 (es)
ID (1) ID23429A (es)
IL (1) IL133076A (es)
IS (1) IS5260A (es)
MA (1) MA24587A1 (es)
NO (1) NO996520L (es)
OA (1) OA11243A (es)
PA (1) PA8454301A1 (es)
PE (1) PE97199A1 (es)
PL (1) PL337804A1 (es)
SK (1) SK181099A3 (es)
TN (1) TNSN98124A1 (es)
TR (1) TR199903297T2 (es)
TW (1) TW550087B (es)
UA (1) UA67741C2 (es)
UY (1) UY25071A1 (es)
WO (1) WO1999001120A1 (es)
YU (1) YU68299A (es)
ZA (1) ZA985708B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2002017918A2 (en) 2000-08-30 2002-03-07 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
KR101500020B1 (ko) * 2007-03-12 2015-03-06 디에스엠 아이피 어셋츠 비.브이. 미용 조성물
EP2520299A1 (en) * 2009-12-29 2012-11-07 Kowa Co., Ltd. Solid pharmaceutical composition for oral administration
EP2520300A4 (en) * 2009-12-29 2013-05-08 Kowa Co PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114894736A (zh) * 2022-05-20 2022-08-12 中化地质矿山总局地质研究院 一种氯化物型卤水中硝酸根的测定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
EP0415612B1 (en) * 1989-08-30 1993-11-10 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
MA24587A1 (fr) 1998-12-31
UY25071A1 (es) 2000-12-29
OA11243A (en) 2003-07-24
UA67741C2 (uk) 2004-07-15
AR015917A1 (es) 2001-05-30
EP0999829A1 (en) 2000-05-17
WO1999001120A1 (en) 1999-01-14
PE97199A1 (es) 1999-10-05
IL133076A (en) 2003-12-10
HUP0002236A3 (en) 2003-12-29
EA199900962A1 (ru) 2000-08-28
CA2290974A1 (en) 1999-01-14
AU742535B2 (en) 2002-01-03
PA8454301A1 (es) 2000-09-29
BG103918A (en) 2000-07-31
TR199903297T2 (xx) 2000-07-21
PL337804A1 (en) 2000-09-11
DZ2548A1 (fr) 2003-02-08
JP2000514100A (ja) 2000-10-24
YU68299A (sh) 2002-06-19
ZA985708B (en) 2000-01-10
IS5260A (is) 1999-11-19
CO4940495A1 (es) 2000-07-24
BR9810739A (pt) 2000-09-12
KR20010013365A (ko) 2001-02-26
HUP0002236A2 (hu) 2003-08-28
AR040279A2 (es) 2005-03-23
CA2290974C (en) 2004-04-27
AP9801280A0 (en) 1998-06-30
TW550087B (en) 2003-09-01
SK181099A3 (en) 2000-07-11
NO996520L (no) 2000-02-29
HN1998000102A (es) 1999-01-08
IL133076A0 (en) 2001-03-19
TNSN98124A1 (fr) 2005-03-15
NO996520D0 (no) 1999-12-28
EA002481B1 (ru) 2002-06-27
AP1192A (en) 2003-07-23
KR100366373B1 (ko) 2003-01-14
ID23429A (id) 2000-04-20
HRP980377A2 (en) 1999-04-30
AU7544898A (en) 1999-01-25
CN1261794A (zh) 2000-08-02

Similar Documents

Publication Publication Date Title
AR000714A1 (es) Un metodo de uso de un agente quelante para mejorar la fidelidad de color de telas lavadas y una composicion para uso en dicho metodo.
ES2159111T3 (es) Composiciones en pastillas para el aseo personal, que contienen un complejo liberador de fragancia.
AR025247A1 (es) Composiciones de granulos de carotenos-xantofilos, estables
NO20033119L (no) Ekspanderbare styrenpolymerer som inneholder karbonpartikler
BR9806443B1 (pt) processo e aparelho para automaticamente compensar o volume de som.
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
EP1057862A3 (en) Polymer film compositions for capsules
ES2185936T3 (es) Composiciones liquidas de limpieza que contienen tensioactivos ramificados en mitad de la cadena seleccionados.
CO4750807A1 (es) Solucion de interferon
RS49795B (sr) Sredstva sa antidepresivnim dejstvom
AR021777A1 (es) UNA COMPOSICIoN PARA ACONDICIONAR, ACLARAR E ILUMINAR EL CABELLO Y UN MÉTODO PARA ACONDICIONAR, ACLARAR E ILUMINAR EL CABELLO.
ES2108592T3 (es) Composicion espesada en medio acuoso y procedimiento de espesamiento de un medio acuoso.
AR040280A2 (es) Procedimiento para aumentar su solubilidad en un medio acuoso
MX9405434A (es) Composicion de peroxido de hidrogeno.
HUP0003055A2 (hu) Glukanáztartalmú tisztítószer kemény felületek számára
HN2001000262A (es) Kit de repinotano
ES2151135T3 (es) Compuesto pulverulento de hidroxipropil-betaciclodextrina y su procedimiento de preparacion.
MX170928B (es) Composicion limpiadora para superficies duras
BR9911464A (pt) Métodos de inibição de corrosão usando isÈmeros de cloro-metilbenzotriazol
ES2168113T3 (es) Disolucion blanqueadora de lactona/peroxido, sistema blanqueador para formar la misma y metodo de preparacion y uso de la misma.
BR9801142A (pt) Novos copolímeros de bloco de siloxano que têm blocos de siloxano ligados
AR020703A1 (es) Barra de limpieza de superficies duras.
ES2177258T3 (es) Procedimiento parra la extraccion de particulas de poliamida 6.
DK0943030T3 (da) Fremgangsmåde til reduktion af svovl- og kypefarvestoffer
ES1036933Y (es) Disposicion de tonel grande, de uso repetido, para productos liquidos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure